www.finanzen.net/analyse/...ics_Buy-H_C_Wainwright__Co__565873
|
seekingalpha.com/article/...conference-presentation-slideshow
plant 60 Mio. $ Offering
seekingalpha.com/news/...ock-offering-shares-12-percent-hours
Details des Offerings
seekingalpha.com/news/...s-therapeutics-prices-stock-offering
positive Phase3 SER-109 Studienergebnisse
ir.serestherapeutics.com/news-releases/...ine-results-ser-109
Phase 2b ECO-RESET Studie von SER-287 (UC) verfehlt den primären Endpunkt
ir.serestherapeutics.com/news-releases/...ts-ser-287-phase-2b
Trotz des Phase2 Flops von SER-287 sollte man Seres nicht abschreiben. Mit SER-109 haben sie noch ein heißes Eisen im Feuer und werden voraussichtlichtlich demnächst einen Zulasungsantrag stellen. Neben den 175 Mio. $ Vorabzahlung von Nestle könnten bei Zulassung nochmal 125 Mio. $ hinzukommen und umsatzbezogene Meilensteinzahlungen bis zu 225 Mio. $.
www.fiercebiotech.com/biotech/...o-as-shares-go-into-freefall
www.fool.com/investing/2021/07/22/...stock-is-crashing-today/
www.fiercebiotech.com/biotech/...r-rights-to-c-diff-treatment
Zahlen für Q1/21
"Following successful SER-109 Phase 3 pivotal results in patients with recurrent C. difficile infection, we continue to enroll an open label study to expand our safety database. We are very pleased with the pace of study enrollment and we anticipate achieving target enrollment during the third quarter of 2021. Completion of the required SER-109 safety database will support a Biologics License Application (BLA) filing, and potentially pave the way for SER-109 to become the first-ever FDA-approved microbiome therapeutic.”
ir.serestherapeutics.com/news-releases/...1-financial-results
Zahlen für Q2/21
– SER-109 open-label study in patients with recurrent C. difficile infection on track to achieve enrollment target in late Q3 2021 –
– SER-109 co-commercialization agreement with Nestlé Health Science provides $310 million in upfront and contingent approval milestones, additional $225 million in contingent sales milestones, and future payments equal to 50% of profits –
ir.serestherapeutics.com/news-releases/...1-financial-results
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 43 | Seres Therapeutics Kursziel 55 USD | Balu4u | Vassago | 06.03.24 17:59 | |
4 | mal sehen | Kapok | Kapok | 25.01.24 16:22 |